Sculptra: the New Three-Dimensional Filler

      Sculptra (Dermik Laboratories, A Division of Aventis Pharmaceuticals, Inc., Berwyn, PA) was approved by the US Food and Drug Administration (FDA) on August 3, 2004 as the first synthetic injectable medical device for the treatment of HIV-related facial lipoatrophy [

      Klein R, Struble K. US Food and Drug Admisinstration. FDA approval of Sculptra for treating HIV facial lipoatrophy. Available at: www.fda.gov//bbs/topics/news/2004/NEW0100.html. Accessed 5/6/06.

      ]. HIV lipodystrophy syndrome is a complication of highly active antiretroviral therapy (HAART) with protease inhibitors (PIs) or nucleoside reverse transcriptase inhibitors (NRTIs) [
      • Kravcik S.
      HIV lipodystrophy: a review.
      ,
      • Mallon P.W.G.
      • Cooper D.A.
      • Carr A.
      HIV-associated lipodystrophy.
      ,
      • John M.
      • Nolan D.
      • Mallal S.
      Antiretroviral therapy and the lipodystrophy syndrome.
      ,
      • Nolan D.
      • John M.
      • Mallal S.
      Antiretroviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
      ,
      • Garcia-Viejo M.A.
      • Ruiz M.
      • Martinez E.
      Strategies for treating HIV-related lipodystrophy.
      ,
      • Qaqish R.B.
      • Fisher E.
      • Rublein J.
      • et al.
      HIV lipodystrophy syndrome.
      ]. HIV lipodystrophy syndrome is characterized by metabolic abnormalities, central fat hypertrophy, and peripheral fat atrophy. Metabolic aberrations (insulin resistance/diabetes, hypercholesterolemia, and hypertriglyceridemia) and central fat hypertrophy are more commonly seen with PIs, whereas NRTIs are more likely to contribute to fat wasting or lipoatrophy [
      • Garcia-Viejo M.A.
      • Ruiz M.
      • Martinez E.
      Strategies for treating HIV-related lipodystrophy.
      ]. Metabolic changes may eventually require medication with oral hypoglycemic, antilipid agents, or both.
      To read this article in full you will need to make a payment
      Purchase one-time access
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.
      Subscribe to Clinics in Plastic Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Klein R, Struble K. US Food and Drug Admisinstration. FDA approval of Sculptra for treating HIV facial lipoatrophy. Available at: www.fda.gov//bbs/topics/news/2004/NEW0100.html. Accessed 5/6/06.

        • Kravcik S.
        HIV lipodystrophy: a review.
        HIV Clin Trials. 2000; 1: 37-50
        • Mallon P.W.G.
        • Cooper D.A.
        • Carr A.
        HIV-associated lipodystrophy.
        HIV Med. 2001; 2: 166-173
        • John M.
        • Nolan D.
        • Mallal S.
        Antiretroviral therapy and the lipodystrophy syndrome.
        Antivir Ther. 2001; 6 ([Review]): 9-20
        • Nolan D.
        • John M.
        • Mallal S.
        Antiretroviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
        Antivir Ther. 2001; 6 ([Review]): 145-160
        • Garcia-Viejo M.A.
        • Ruiz M.
        • Martinez E.
        Strategies for treating HIV-related lipodystrophy.
        Expert Opin invest Drugs. 2001; 10: 1443-1456
        • Qaqish R.B.
        • Fisher E.
        • Rublein J.
        • et al.
        HIV lipodystrophy syndrome.
        Pharmacotherapy. 2000; 20: 13-22
      2. Torres R, Dadman J, Kassous J, et al. Long term follow-up of patients with HIV receiving rhGH: another dilemma of early versus delayed intervention? Presented at the 13th International AIDS Conference. Durban, South Africa, July, 2000. Abstract WePeB4234.

        • Chastain M.A.
        • Buckley-Chastain J.
        • Coleman W.P.
        HIV lipodystrophy: review of the syndrome and report of a case treated with liposuction.
        Dermatol Surg. 2001; 27: 497-500
        • Carr A.
        • Cooper D.A.
        Adverse effects of antiretroviral therapy.
        Lancet. 2000; 356: 1423-1430
        • Berger J.R.
        • Pall L.
        • Hall C.D.
        • et al.
        Oxandrolone in AIDS-wasting myopathy.
        AIDS. 1996; 10: 1657-1662
        • Gold J.
        • High H.A.
        • Li Y.
        • et al.
        Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection.
        AIDS. 1996; 10: 745-752
        • Ritt M.J.
        • Hillebrand-Haverkort M.E.
        • Ten Veen J.H.
        Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy.
        Acta Chir Plast. 2001; 43: 54-56
      3. O'Donovan CA, Hourihan M, Petrak J, et al. Psychosocial adjustment to facial lipoatrophy in people with HIV. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland, November 13–16, 2005. Abstract 34. Antiviral Ther 2005;10:L24.

      4. Sculptra™ (package insert). Berwyn (PA): Dermik Laboratories. August 2004.

        • Valantin M.
        • Aubron-Olivier C.
        • Ghosn J.
        • et al.
        Polylactic acid implants (New-Fill®) to correct facial lipoatrophy in HIV infected patients: results of the open-label study VEGA.
        AIDS. 2003; 17: 2471-2477
        • Moyle G.J.
        • Lysakova L.
        • Brown S.
        • et al.
        A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection.
        HIV Med. 2004; 5: 82-87
        • Donofrio L.M.
        Fat distribution: a morphologic study of the aging face.
        Dermatol Surg. 2000; 26: 1107-1112
        • Vleggaar D.
        Facial enhancement and the European experience with Sculptra™.
        J Drugs Dermatol. 2004; 3: 542-547
        • Gogolewski S.
        • Jovanovic M.
        • Perren S.M.
        • et al.
        Tissue response and in vivo degradation of selected polyhydroxacids: polyactides (PLA), poly (3-hydroxybutyrate) (PHB), and poly (3-hydroxybutyrate-co-3-hydroxyvalerated) (PHB/VA).
        J Biomed Mater Res. 1993; 27: 1135-1148